FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2795865692> ?p ?o ?g. }

• W2795865692 abstract "750 Background: The alternate-days administration of S-1 was suggested to reduce toxicities such as GI-related adverse events (AEs) or neutropenia maintaining efficacy in some previous reports. This phase II study was aimed to evaluate an alternate-day administration of S-1 combined with bevacizumab in untreated elderly patients with mCRC. Methods: The key eligibility criteria included age ≥75 years, first-line chemotherapy, measurable lesions, Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1, preserved organ function, and refusal of oxaliplatin- or irinotecan-containing regimen as the initial chemotherapy. Patients received 40 mg (body surface area [BSA] ≤1.25 m 2 ), 50 mg (BSA > 1.25 to ≤1.50 m 2 ), or (BSA > 1.50 m 2 ) of S-1 orally, twice a day, on Monday, Wednesday, Friday, and Sunday every week. Bevacizumab of 7.5 mg/kg was administered every 3 weeks. Primary endpoint was progression-free survival (PFS). Expected median PFS was 8.5 months, and efficacy threshold was 5.0 months. The required sample size was calculated as 50 patients, with a 2-sided type I error of 10% and a power of 80%. Results: Of 54 enrolled patients, 50 patients for efficacy and 53 patients for safety were evaluated. The median age was 79 years (range, 75–88), and 56% had an ECOG PS of 0. The median follow-up time was 34.5 months (95% confidence interval [CI], 25.6–44.9). Median PFS was 8.1 months (95%CI, 7.4–10.1). Median overall survival was 22.8 months (95%CI, 16.9–28.5). The response rate and disease control rate were 44% and 88%, respectively. Grade 3 or more hematologic, non-hematologic, and bevacizumab-related AEs were observed in 9%, 11%, and 25% of patients, respectively. The most common grade 3 and 4 treatment-related adverse events were hypertension (11%), nausea (6%), fatigue (6%), anemia (6%), and proteinuria (6%). Treatment-related death caused by cerebral infarction was observed in one patient. Conclusions: The primary endpoint was met. The alternate-days administration of S-1 combined with bevacizumab was well tolerated and effective in elderly patients with mCRC. Clinical trial information: UMIN000010402." @default.
• W2795865692 created "2018-04-13" @default.
• W2795865692 creator A5007353694 @default.
• W2795865692 creator A5012088444 @default.
• W2795865692 creator A5016038702 @default.
• W2795865692 creator A5023842343 @default.
• W2795865692 creator A5028248936 @default.
• W2795865692 creator A5035293914 @default.
• W2795865692 creator A5038876397 @default.
• W2795865692 creator A5044877688 @default.
• W2795865692 creator A5053050318 @default.
• W2795865692 creator A5053509708 @default.
• W2795865692 creator A5055485868 @default.
• W2795865692 creator A5062868734 @default.
• W2795865692 creator A5066565101 @default.
• W2795865692 creator A5069791653 @default.
• W2795865692 creator A5087382275 @default.
• W2795865692 creator A5089442498 @default.
• W2795865692 date "2018-02-01" @default.
• W2795865692 modified "2023-09-23" @default.
• W2795865692 title "Phase II study of S-1 on alternate days combined with bevacizumab in elderly patients (aged ≥75 years) with metastatic colorectal cancer (mCRC)." @default.
• W2795865692 doi "https://doi.org/10.1200/jco.2018.36.4_suppl.750" @default.
• W2795865692 hasPublicationYear "2018" @default.
• W2795865692 type Work @default.
• W2795865692 sameAs 2795865692 @default.
• W2795865692 citedByCount "0" @default.
• W2795865692 crossrefType "journal-article" @default.
• W2795865692 hasAuthorship W2795865692A5007353694 @default.
• W2795865692 hasAuthorship W2795865692A5012088444 @default.
• W2795865692 hasAuthorship W2795865692A5016038702 @default.
• W2795865692 hasAuthorship W2795865692A5023842343 @default.
• W2795865692 hasAuthorship W2795865692A5028248936 @default.
• W2795865692 hasAuthorship W2795865692A5035293914 @default.
• W2795865692 hasAuthorship W2795865692A5038876397 @default.
• W2795865692 hasAuthorship W2795865692A5044877688 @default.
• W2795865692 hasAuthorship W2795865692A5053050318 @default.
• W2795865692 hasAuthorship W2795865692A5053509708 @default.
• W2795865692 hasAuthorship W2795865692A5055485868 @default.
• W2795865692 hasAuthorship W2795865692A5062868734 @default.
• W2795865692 hasAuthorship W2795865692A5066565101 @default.
• W2795865692 hasAuthorship W2795865692A5069791653 @default.
• W2795865692 hasAuthorship W2795865692A5087382275 @default.
• W2795865692 hasAuthorship W2795865692A5089442498 @default.
• W2795865692 hasConcept C121608353 @default.
• W2795865692 hasConcept C126322002 @default.
• W2795865692 hasConcept C143998085 @default.
• W2795865692 hasConcept C2776694085 @default.
• W2795865692 hasConcept C2777802072 @default.
• W2795865692 hasConcept C526805850 @default.
• W2795865692 hasConcept C71924100 @default.
• W2795865692 hasConceptScore W2795865692C121608353 @default.
• W2795865692 hasConceptScore W2795865692C126322002 @default.
• W2795865692 hasConceptScore W2795865692C143998085 @default.
• W2795865692 hasConceptScore W2795865692C2776694085 @default.
• W2795865692 hasConceptScore W2795865692C2777802072 @default.
• W2795865692 hasConceptScore W2795865692C526805850 @default.
• W2795865692 hasConceptScore W2795865692C71924100 @default.
• W2795865692 hasLocation W27958656921 @default.
• W2795865692 hasOpenAccess W2795865692 @default.
• W2795865692 hasPrimaryLocation W27958656921 @default.
• W2795865692 hasRelatedWork W1412044215 @default.
• W2795865692 hasRelatedWork W1859421745 @default.
• W2795865692 hasRelatedWork W1909809492 @default.
• W2795865692 hasRelatedWork W1988706862 @default.
• W2795865692 hasRelatedWork W1989484965 @default.
• W2795865692 hasRelatedWork W2041251610 @default.
• W2795865692 hasRelatedWork W2100460633 @default.
• W2795865692 hasRelatedWork W2102930645 @default.
• W2795865692 hasRelatedWork W2187553531 @default.
• W2795865692 hasRelatedWork W2324888499 @default.
• W2795865692 hasRelatedWork W2337096498 @default.
• W2795865692 hasRelatedWork W2736995408 @default.
• W2795865692 hasRelatedWork W2770311411 @default.
• W2795865692 hasRelatedWork W2890631345 @default.
• W2795865692 hasRelatedWork W3017010154 @default.
• W2795865692 hasRelatedWork W3031352853 @default.
• W2795865692 hasRelatedWork W3197137235 @default.
• W2795865692 hasRelatedWork W3201612254 @default.
• W2795865692 hasRelatedWork W1817246953 @default.
• W2795865692 hasRelatedWork W2909787771 @default.
• W2795865692 isParatext "false" @default.
• W2795865692 isRetracted "false" @default.
• W2795865692 magId "2795865692" @default.
• W2795865692 workType "article" @default.